Good clinical practice recommendations for the use of PET/CT in oncology.
Computed tomography
Methodological approval
Positron emission tomography
Journal
European journal of nuclear medicine and molecular imaging
ISSN: 1619-7089
Titre abrégé: Eur J Nucl Med Mol Imaging
Pays: Germany
ID NLM: 101140988
Informations de publication
Date de publication:
01 2020
01 2020
Historique:
received:
23
06
2019
accepted:
24
09
2019
pubmed:
23
10
2019
medline:
15
5
2021
entrez:
23
10
2019
Statut:
ppublish
Résumé
Positron emission tomography/computed tomography (PET/CT) is a nuclear medicine functional imaging technique with proven clinical value in oncology. PET/CT indications are continually evolving with fresh advances made through research. French practice on the use of PET in oncology was framed in recommendations based on Standards-Options-Recommendations methodology and coordinated by the French federation of Comprehensive Cancer Centres (FNLCC). The recommendations were originally issued in 2002 followed by an update in 2003, but since then, a huge number of scientific papers have been published and new tracers have been licenced for market release. The aim of this work is to bring the 2003 version recommendations up to date. For this purpose, a focus group was set up in collaboration with the French Society for Nuclear Medicine (SFMN) to work on developing good clinical practice recommendations. These good clinical practice recommendations have been awarded joint French National Heath Authority (HAS) and French Cancer Institute (INCa) label status-the stamp of methodological approval. The present document is the outcome of comprehensive literature review and rigorous appraisal by a panel of experts, organ specialists, clinical oncologists, surgeons and imaging specialists. These data were also used for the EANM referral guidelines.
Identifiants
pubmed: 31637482
doi: 10.1007/s00259-019-04553-8
pii: 10.1007/s00259-019-04553-8
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
28-50Références
Radiat Oncol. 2016 Mar 11;11:37
pubmed: 26968955
Urol Int. 2019;102(1):27-36
pubmed: 30269140
Eur J Nucl Med Mol Imaging. 2014 Mar;41(3):416-27
pubmed: 24258007
Eur Urol Focus. 2018 Sep;4(5):702-706
pubmed: 28753797
J Urol. 2016 May;195(5):1436-1443
pubmed: 26682756
Eur Radiol. 2019 Mar;29(3):1221-1230
pubmed: 30132104
J Clin Oncol. 2002 Jan 15;20(2):379-87
pubmed: 11786564
J Urol. 2019 Apr;201(4):815-820
pubmed: 30672842
Eur J Nucl Med Mol Imaging. 2016 Jul;43(8):1410-7
pubmed: 26993315
Eur J Clin Invest. 2019 Mar;49(3):e13063
pubmed: 30580449
Eur J Nucl Med Mol Imaging. 2011 Mar;38(3):426-35
pubmed: 21057787
Prostate Int. 2017 Dec;5(4):125-129
pubmed: 29188197
Eur J Nucl Med Mol Imaging. 2002 Oct;29(10):1317-23
pubmed: 12271413
Eur Urol Focus. 2018 Sep;4(5):686-693
pubmed: 28753806
J Nucl Med. 2018 Jan;59(1):82-88
pubmed: 28646014
Clin Nucl Med. 2016 Jul;41(7):515-21
pubmed: 26975008
Eur J Nucl Med Mol Imaging. 2017 Apr;44(4):678-688
pubmed: 27889802
Cancer Radiother. 2019 Jun;23(3):194-200
pubmed: 31088725
Eur Urol. 2018 Aug;74(2):179-190
pubmed: 29678358
Clin Nucl Med. 2019 May;44(5):365-376
pubmed: 30888999
Eur Urol. 2016 Dec;70(6):926-937
pubmed: 27363387
Int J Radiat Oncol Biol Phys. 2019 Jan 1;103(1):95-104
pubmed: 30201438
Eur J Nucl Med Mol Imaging. 2014 Jan;41(1):11-20
pubmed: 24072344
Urology. 2019 Mar;125:154-162
pubmed: 30580002
J Nucl Med. 2016 Nov;57(11):1713-1719
pubmed: 27261524
Hell J Nucl Med. 2017 Sep-Dec;20 Suppl:156
pubmed: 29324926
Eur Urol. 2019 Feb 14;:null
pubmed: 30773328